# Agent 4 Benchmark Report - 15_recovery

**Generated:** 2026-06-03 12:57:05
**Agent:** 4
**Category:** 15_recovery

## Executive Summary

| Metric | Value |
|--------|-------|
| Total Tests | 40 |
| Passed | 16 |
| Failed | 24 |
| Pass Rate | 40.0% |
| Avg Score | 0.752 |

### Failure Root Causes

| Root Cause | Count | % of Failures | Severity |
|------------|-------|---------------|----------|
| wrong_answer | 20 | 83.3% | P2 |
| keyword_missing | 4 | 16.7% | P2 |

## Detailed Results

### ✅ Q0921

**Input:** During a brachytherapy treatment, the nurse reports that the patient is experiencing unexpected pain during source dwell. The physicist determines that the source is dwelling at a position 3 mm from where it should be according to the plan. Describe the immediate response, dose assessment for the patient, and the investigation into the source positioning error....

**Response:**
> ## Immediate Response**Step 1: Patient Safety**- Immediately pause treatment and verify source position- Assess patient condition - pain evaluation, vital signs- Do NOT attempt manual source manipulation**Step 2: Source Control**- Verify afterloader status and attempt normal retraction sequence- If source fails to retract, implement stuck source protocol per AAPM TG-56:  - Move non-essential personnel to adjacent areas  - Keep patient as calm as possible to minimize movement  - Contact RSO and radiation safety team## Dose Assessment**For a 3 mm dwell position error:**| Parameter | Analysis Required ||-----------|-------------------|| Dwell time at erroneous position | What fraction of planned time was delivered? || Distance from planned position | 3 mm = potential for significant dose deviation || Organ at risk proximity...

**Scores:**
- Total: 0.77
- Keyword: 0.33
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0921](../screenshots/15_Q0921.png)

---

### ✅ Q0922

**Input:** A brachytherapy center discovers that one of its applicator sets has a manufacturing defect where the ring applicator diameter is 1 mm smaller than specifications. This defect was present since the applicator was purchased 6 months ago. Assess the impact of this defect on previously delivered treatments and determine the necessary corrective actions....

**Response:**
> ## Manufacturing Defect Assessment: Ring Applicator Diameter 1mm Below Specification### 1. Immediate Actions**Quarantine the defective applicator set** immediately and mark as "Do Not Use."**Contact the manufacturer** to:- Report the defect- Request replacement applicators- Obtain detailed manufacturing records- Determine if other applicators in the same lot are affected### 2. Impact Assessment**Dosimetric Impact Calculation:**For HDR brachytherapy, a 1mm diameter reduction means:- Increased air gap between applicator and tissue- Changed source-to-tissue distance at prescription point- Dose error follows inverse square law approximationFor a typical ring diameter prescription at 5mm depth:| Diameter Error | Approximate Dose Error...

**Scores:**
- Total: 0.82
- Keyword: 0.50
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0922](../screenshots/15_Q0922.png)

---

### ✅ Q0923

**Input:** A treatment plan review committee identifies that 10% of brachytherapy plans reviewed over the past quarter had documentation deficiencies, including missing dose parameters, incomplete organ-at-risk reporting, and absent plan comparison documentation. Develop a corrective action plan to address these systematic documentation gaps....

**Response:**
> # Corrective Action Plan: Brachytherapy Documentation Deficiencies## Executive SummaryA 10% documentation deficiency rate represents a significant quality gap requiring immediate intervention. Based on the described deficiencies (missing dose parameters, incomplete OAR reporting, absent plan comparisons), this plan addresses root causes and implements sustainable improvements.---## 1. Root Cause Analysis**Immediate Contributing Factors:**| Deficiency Type | Likely Root Cause | Investigation Method ||-----------------|-------------------|----------------------|| Missing dose parameters | Incomplete checklist or TPS output configuration | Audit TPS report templates || Incomplete OAR reporting | Lack of standardized reporting protocol | Review current OAR contouring workflow || Absent plan comparison | No requirement for comparison documentation | Assess policy requirements |**Systemic Contributing Factors:**- No standardized plan review checklist- Physician signature obtained before comp...

**Scores:**
- Total: 0.94
- Keyword: 0.83
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0923](../screenshots/15_Q0923.png)

---

### ✅ Q0924

**Input:** During quality assurance testing, the well chamber reading shows a 2% decrease in source strength compared to the previous monthly measurement, which is within normal decay expectations. However, the physicist notes that the temperature and pressure corrections were not applied to the current reading. Recalculate the corrected source strength and evaluate whether the reading is consistent with expected decay....

**Response:**
> ## Well Chamber Source Strength Correction Analysis### 1. Expected Decay Calculation**Ir-192 source characteristics:**- Half-life: 73.83 days- Monthly decay rate: approximately **2.2-2.5% per 30 days**For a 30-day interval, expected decay:```Decay factor = e^(-λ × t) where λ = ln(2)/73.83Decay factor ≈ 0.978 (≈2.2% decrease)```### 2. Temperature and Pressure CorrectionThe well chamber reading must be corrected to standard conditions (22°C, 760 mmHg):**Correction formula (AAPM TG-51):**```Nk (corrected) = Nk (measured) × [(PT...

**Scores:**
- Total: 0.88
- Keyword: 0.67
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0924](../screenshots/15_Q0924.png)

---

### ✅ Q0925

**Input:** A center discovers that its brachytherapy treatment records for the past 3 months are missing the required physicist signature on 15% of plans. This represents a documentation compliance gap. Assess the regulatory implications, determine whether treatment validity is affected, and develop a corrective action plan....

**Response:**
> This is a legitimate quality assurance and compliance question. Here's a comprehensive analysis:---## Regulatory Implications**Licensing Requirements:**- **NRC/Agreement State regulations** (10 CFR 35 for byproduct material) require physicist oversight and signature verification for brachytherapy treatments- **JCAHO/The Joint Commission** standards mandate documented QA review- **State radiation control programs** typically require documented physicist signature as condition of license- Missing signatures on 15% of plans represents a **license violation** that could trigger regulatory action**Accreditation Impact:**- **ACR-AAPM accreditation** requires documented QA processes- Could affect center...

**Scores:**
- Total: 0.77
- Keyword: 0.33
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0925](../screenshots/15_Q0925.png)

---

### ✅ Q0926

**Input:** A physicist reviewing a brachytherapy plan discovers that the wrong applicator model was selected in the treatment planning system. The plan was calculated with a ring applicator model that has a 3 mm larger diameter than the actual applicator used. Determine the dose calculation impact of this error and the corrective actions needed....

**Response:**
> ## Wrong Applicator Model Selection: Dose Impact and Corrective Actions### **Dose Calculation Impact****Source-to-Tissue Distance Error:**- A 3 mm larger ring diameter means the actual applicator sits **1.5 mm closer** to the target tissue on all sides- This reduces the source-to-prescription point distance**Dosimetric Consequences:**| Parameter | Effect ||-----------|--------|| **Dose rate at prescription point** | ~5-10% higher than calculated || **HR-CTV dose coverage** | Potentially over-treated by 5-10% || **OAR doses (rectum, bladder)** | May be underestimated by 5-10% || **Dwell position accuracy** | Generally preserved (geometry unchanged) |The effect...

**Scores:**
- Total: 0.82
- Keyword: 0.50
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0926](../screenshots/15_Q0926.png)

---

### ✅ Q0927

**Input:** A center's brachytherapy program experienced a situation where two patients with similar names were scheduled for treatment on the same day. During the patient identification verification process, a near-miss event occurred where the wrong patient was brought to the treatment room before the error was caught. Describe the complete response including immediate actions, investigation, and system improvements....

**Response:**
> This is a serious patient safety near-miss event. Here's a comprehensive response:## Immediate Actions**Stop the process immediately:**- Verify the correct patient was NOT treated (no radiation delivered)- Return the correct patient to the waiting area with appropriate explanation- Document the event in real-time in the treatment record- Notify the treating physician and department head- Notify the radiation safety officer (RSO)**Patient communication:**- Explain to the wrong patient (who was brought in) what happened, apologize, and reassure them no radiation was delivered- Explain to the correct patient the delay and reason- Both conversations should be documented verbatim## Investigation**Root Cause Analysis (RCA):**- Interview all staff involved: nurses, therapists, physicist...

**Scores:**
- Total: 0.77
- Keyword: 0.33
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0927](../screenshots/15_Q0927.png)

---

### ✅ Q0928

**Input:** During an audit, it is discovered that the brachytherapy program has been using outdated organ-at-risk dose constraints that do not reflect current GEC-ESTRO or QUANTEC recommendations. Plans that would have been flagged under current constraints were approved under the outdated limits. Assess the clinical impact and determine which patients need to be re-evaluated....

**Response:**
> # Audit Finding: Outdated OAR Dose Constraints in Brachytherapy## 1. Clinical Impact Assessment**Immediate Analysis Required:**- Identify which specific OAR constraints were outdated- Determine the magnitude of constraint differences- Assess whether any plans would have triggered alerts under current guidelines**Common Outdated Constraints:**| Organ | Old Constraint | Current GEC-ESTRO/QUANTEC | Clinical Significance ||-------|----------------|---------------------------|----------------------|| Rectum D2cc | 70-75 Gy | 70-75 Gy EQD2 | Generally aligned || Bladder D2cc | 80-90 Gy | 80-90 Gy EQD2 | Generally aligned || Sigmoid D2cc | 70 Gy | 70...

**Scores:**
- Total: 0.94
- Keyword: 0.83
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0928](../screenshots/15_Q0928.png)

---

### ✅ Q0998

**Input:** During a brachytherapy quality assurance review, it is discovered that the treatment planning system has been using an outdated TG-43 data file for a specific applicator type that was replaced 6 months ago. All plans using this applicator type during the intervening period may have been calculated with incorrect dose data. Perform a comprehensive risk assessment, describe the investigation methodology, and outline the corrective actions needed....

**Response:**
> ## Comprehensive Analysis: Outdated TG-43 Data File Incident### 1. Risk Assessment**Potential Impact Calculation:**| Parameter | Typical TG-43 Change | Patient Impact (6 months) ||-----------|---------------------|---------------------------|| Air-kerma strength constant | ±0.5-2% | Systematic dose error || Dose-rate constant | ±1-3% | Uniform scaling || Anisotropy function | ±2-5% | Position-dependent || Radial dose function | ±1-2% | Depth-dependent |**For Ir-192 HDR (most common):**- Dose-rate constant typically 1.108-1.113 cGy/h·U- A 0.5% change = systematic 0.5% dose error across all patients- Over 6 months (~100+...

**Scores:**
- Total: 0.77
- Keyword: 0.33
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q0998](../screenshots/15_Q0998.png)

---

### ✅ Q1840

**Input:** HDR source gets stuck during treatment of cervical cancer. The dwell position 3 in the tandem will not retract after delivering 2 Gy of a planned 6 Gy fraction. The source is partially exposed. What immediate steps should the physicist take? What is the radiation exposure to the patient and staff? Should the treatment be continued or abandoned? How do I document this incident?...

**Response:**
> This is a real emergency scenario. Here's the proper response:## Immediate Steps for Physicist**1. Activate emergency source retraction protocol:**- Do NOT attempt manual source manipulation- Use the afterloader's emergency retraction system (typically manual crank or backup mechanism)- If primary retraction fails, consult vendor emergency procedures for your specific afterloader model**2. Notify radiation safety officer (RSO) immediately****3. Clear non-essential personnel from the treatment room****4. Assess the situation:**- Determine if source can be fully retracted to safe position- Document dwell position, time delivered, and clinical circumstances## Radiation Exposure**Patient exposure:**- At dwell position 3 (proximal tandem), the delivered dose is approximately 2 Gy- This is within normal treatment range; no immediate medical intervention needed for patient- Patient should remain in place until source is secured**Staff exposure:**- Ir-192 HDR...

**Scores:**
- Total: 0.79
- Keyword: 0.40
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1840](../screenshots/15_Q1840.png)

---

### ❌ Q1841

**Input:** During prostate LDR seed implantation, 3 seeds are found to have migrated to the lungs on post-implant chest X-ray. The patient is asymptomatic. What is the clinical significance of seed migration to the lungs? What management is required? Should I modify the post-implant dosimetry? What documentation and reporting requirements exist?...

**Response:**
> ## Seed Migration to Lungs: Clinical Significance and Management### Clinical Significance**Incidence**: Seed migration to the lungs occurs in approximately 2-10% of prostate seed implants, with most migrations involving 1-3 seeds.**Why lungs?** Seeds migrate through periprostatic veins → iliac veins → right heart → pulmonary arteries. The right lung is more common due to anatomy.**Clinical impact**: Generally **minimal**. Lung seed migration is typically asymptomatic with no known long-term complications because:- Each I-125 or Pd-103 seed delivers very low activity (0.3-0.5 mCi)- Lung tissue has high radiation tolerance- Seeds become encapsulated and stop emitting significant dose### Management| Action | Recommendation ||--------|----------------|| **Patient counseling** | Explain finding...

**Scores:**
- Total: 0.72
- Keyword: 0.20
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1841](../screenshots/15_Q1841.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ✅ Q1842

**Input:** A brachytherapy treatment plan was delivered to the wrong patient. The physicist discovers the error during the chart check after treatment. The patient received the planned dose but for the wrong disease site. What immediate steps should be taken? What is the reporting requirement? How should this incident be managed from a clinical and legal perspective?...

**Response:**
> ## Wrong-Patient Brachytherapy Treatment: Incident Response### Immediate Clinical Actions**1. Stop and Assess (Day 0)**- Verify the error through independent chart review- Determine exact dose delivered and treatment site- Assess clinical impact on both patients (treated and missed)**2. Patient Management**| Patient Who Received Wrong Treatment | Patient Who Missed Treatment ||-------------------------------------|------------------------------|| Medical evaluation of unintended treatment site | Assess disease progression during delay || Monitor for acute toxicity at treated site | Expedite correct treatment ASAP || Document as "unintended radiation exposure" | Document as "missed treatment" |**3. Notify Treating Physician and RSO Immediately**---### Dose Assessment...

**Scores:**
- Total: 0.86
- Keyword: 0.60
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1842](../screenshots/15_Q1842.png)

---

### ✅ Q1843

**Input:** During HDR brachytherapy for cervical cancer, the afterloader reports an air-kerma rate that is 15% lower than expected for the current source age. The source was last calibrated 3 months ago. What could cause this discrepancy? Should the treatment proceed? What verification steps should be performed? Should the vendor be contacted?...

**Response:**
> ## HDR Afterloader Air-Kerma Rate Discrepancy: Clinical Physics Analysis### Immediate Assessment**15% lower than expected = Do NOT proceed with treatment**This discrepancy is clinically significant and requires thorough investigation before any treatment.---### Potential Causes| Category | Specific Cause | Likelihood ||----------|----------------|------------|| **Measurement error** | Well chamber miscalibration | High || **Source certificate error** | Incorrect value on manufacturer certificate | Moderate || **Decay calculation error** | Wrong half-life or calculation error in TPS | Moderate || **Environmental factors** | Temperature/pressure not accounted for |...

**Scores:**
- Total: 0.79
- Keyword: 0.40
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1843](../screenshots/15_Q1843.png)

---

### ❌ Q1844

**Input:** After prostate LDR seed implantation, the post-implant CT shows that 8 seeds were placed outside the prostate capsule, with 3 seeds in the bladder wall and 5 in the periprostatic fat. The planned D90 was 185 Gy, but the actual D90 is 142 Gy. What went wrong? How should this underdosage be managed? Should a supplemental treatment be considered?...

**Response:**
> ## Post-Implant Dosimetry Analysis: Prostate Seed Migration and Underdosage### Clinical Situation- **Planned D90:** 185 Gy → **Actual D90:** 142 Gy (23% underdosage)- **Seeds outside capsule:** 8 of ~50 implanted (15-16%)- **Location:** 3 bladder wall, 5 periprostatic fat---### Root Cause Analysis**Potential causes of seed misplacement:**| Cause | Evidence ||-------|----------|| Pre-planning mismatch | Prostate volume or shape didn't match plan || pubic arch interference | Anterior prostate positioning blocked posterior needles || Intraoperative visualization | Poor TRUS guidance in challenging anatomy || Seed migration | Bladder seeds likely migrated post-implant |---### Management Approach**Step 1: Evaluate...

**Scores:**
- Total: 0.72
- Keyword: 0.20
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1844](../screenshots/15_Q1844.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ❌ Q1845

**Input:** During brachytherapy treatment delivery, the treatment planning system crashes mid-treatment. The patient has received 3 of 5 planned dwell positions. The source is retracted to the safe position. What steps should be taken to resume treatment? Can the remaining dwell positions be delivered? How do I ensure dose accuracy for the remainder?...

**Response:**
> ## HDR Treatment Interruption: TPS Crash Mid-Delivery### Immediate Actions (0-5 minutes)1. **Confirm source safety position** — Verify source is fully retracted into safe position (check afterloader display, radiation monitor)2. **Patient care** — Reassure patient, maintain applicator position, do NOT remove applicator3. **Notify radiation oncologist** — Clinical decision required on how to proceed4. **Document exact delivered fraction** — Record which dwell positions were completed and their delivered times### Dose Assessment**Calculate delivered dose:**- Identify which dwell positions were completed- Sum the delivered dwell time at each position- Compare to planned dwell time at each position- Calculate delivered dose to target and OARs**Example calculation:**| Position | Planned Time | Delivered Time | %...

**Scores:**
- Total: 0.72
- Keyword: 0.20
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1845](../screenshots/15_Q1845.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ❌ Q1846

**Input:** The physicist discovers that the wrong TG-43 data was loaded in the treatment planning system for Ir-192 source. The dose-rate constant was entered as 1.108 instead of 1.113. All treatments in the past month used this incorrect data. What is the dosimetric impact? How many patients are affected? What clinical action is needed? How should this be reported?...

**Response:**
> ## TG-43 Data Error Analysis: Dose-Rate Constant Discrepancy### Dosimetric Impact| Parameter | Value ||-----------|-------|| Correct Λ | 1.113 cGy/h/U || Entered Λ | 1.108 cGy/h/U || Error magnitude | **-0.45%** || Patient impact | Underdelivery of 0.45% |This error results in **systematic underdelivery** of approximately 0.45% of the prescribed dose for all affected treatments.### Clinical Significance Assessment**For HDR cervical brachytherapy (4-5 fractions):**- Cumulative underdelivery: ~2% total (marginal)- Likely within normal variation and unlikely to cause local failure- However, formal review is still required**For HDR prostate boost:**- Single or 2-fraction treatments- 0.45% discrepancy = minimal clinical impact### Investigation Steps1. **Identify affected patients**:...

**Scores:**
- Total: 0.72
- Keyword: 0.20
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1846](../screenshots/15_Q1846.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ✅ Q1847

**Input:** A patient receiving brachytherapy develops sudden severe abdominal pain during applicator insertion. CT shows perforation of the sigmoid colon with the applicator tip. What immediate steps should be taken? How should the brachytherapy be managed? What are the implications for future treatment? What documentation is needed?...

**Response:**
> This is a medical emergency requiring immediate response. Here is the management protocol:## Immediate Actions (0-30 minutes)**Patient Safety:**1. Stop the procedure immediately2. Leave applicator in place (provides landmarks for surgical repair)3. Activate emergency response - surgery consultation4. NPO status, IV access, vital sign monitoring5. Pain management per anesthesiology**Radiation Considerations:**- If source was not yet inserted: no radiation hazard- If source was inserted: consult RSO for source retrieval protocol- Do NOT proceed with treatment## Clinical Assessment**Perforation Classification...

**Scores:**
- Total: 0.79
- Keyword: 0.40
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1847](../screenshots/15_Q1847.png)

---

### ❌ Q1848

**Input:** During post-implant dosimetry for prostate LDR brachytherapy, the physicist notices that the prescription dose was entered incorrectly as 145 Gy instead of the planned 125 Gy. The patient has already received the implant. The D90 shows 165 Gy (which is appropriate for 145 Gy prescription). What is the impact of the higher-than-planned dose? How should this be managed?...

**Response:**
> This is a significant planning error. Let me provide a comprehensive clinical analysis:## Error Summary| Parameter | Intended | Delivered ||-----------|----------|-----------|| Prescription | 125 Gy | 145 Gy || Actual D90 | ~125 Gy | 165 Gy || **Overdose** | — | **~32%** |---## Clinical Impact Assessment**For prostate LDR with I-125:**The delivered dose of 165 Gy represents a substantial overtreatment. The consequences include:| OAR | Expected at 125 Gy | Actual at 165 Gy | Risk Increase ||-----|-------------------|------------------|--------------|| **Urethra** | D10 <200 Gy | D10 ~220+ Gy | Significant ↑ || **Rectum** | V100 minimal...

**Scores:**
- Total: 0.72
- Keyword: 0.20
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1848](../screenshots/15_Q1848.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ✅ Q1849

**Input:** The brachytherapy afterloader fails its daily QA check. The source position accuracy test shows the source stops 4 mm from the intended position. There are 3 patients scheduled for treatment today. What are the immediate actions? Can any patients be safely treated? What is the repair protocol? Should alternative equipment be sought?...

**Response:**
> ## HDR Afterloader QA Failure: Immediate Management### **Immediate Actions**1. **Take the afterloader out of service** — Tag it as non-functional, prevent use2. **Contact the service engineer** — Report the failure, request emergency service3. **Notify the radiation oncologist and RSO** — Determine plan for scheduled patients4. **Document the failure** — Record all QA measurements, error messages, and actions taken### **Source Position Accuracy Assessment**| Parameter | Your Result | Tolerance | Status ||-----------|-------------|-----------|--------|| Source position | 4 mm error | ±2 mm (AAPM TG-56) | **FAILS** || Dwell time accuracy | Should verify | ±2% | Pending |...

**Scores:**
- Total: 0.79
- Keyword: 0.40
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1849](../screenshots/15_Q1849.png)

---

### ❌ Q1850

**Input:** A patient who received HDR brachytherapy for cervical cancer develops severe rectal bleeding 3 months after treatment. Flexible sigmoidoscopy shows a radiation-induced rectal ulcer at the treatment site. The rectal D2cc was 72 Gy EQD2 in the treatment plan. What is the management approach for this late complication? Should the treatment plan be reviewed? What grade is this toxicity?...

**Response:**
> ## Management of Rectal Bleeding After Cervical Brachytherapy### Toxicity GradingBased on CTCAE v5.0, this presentation is consistent with **Grade 3 rectal toxicity**:| Grade | Description | This Patient ||-------|-------------|--------------|| Grade 1 | Mild symptoms, intervention not indicated | — || Grade 2 | Moderate symptoms, intervention indicated | — || **Grade 3** | **Severe symptoms, intervention or hospitalization required** | **✓ Severe bleeding, ulcer confirmed** || Grade 4 | Life-threatening consequences | — || Grade 5 | Death | — |### Was 72 Gy EQD2 Acceptable?**Yes, this dose is within acceptable limits.**| Constraint | Standard Limit (GEC-ESTRO) | This Plan ||------------|---------------------------|-----------|| Rectum D2cc | ≤70-75 Gy EQD2 | 72 Gy EQD2 ✓ |The dose is at...

**Scores:**
- Total: 0.72
- Keyword: 0.20
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1850](../screenshots/15_Q1850.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ❌ Q1851

**Input:** During interstitial brachytherapy for breast cancer, one of the needles bends during insertion. The needle tip is 8 mm from the planned position. The treatment plan was based on the planned needle positions. What adjustments should be made? Should the plan be recalculated? What are the dosimetric implications of the misplaced needle?...

**Response:**
> ## Bent Needle During Interstitial Breast Brachytherapy### Immediate Assessment**When a needle bends during insertion:**1. **Do not force** - Stop insertion immediately2. **Assess position** - Verify bent needle location with ultrasound or CT3. **Evaluate trajectory** - Determine if needle can still be used or should be removed4. **Document** - Record exact position, degree of bending, and clinical decision### Dosimetric Impact of 8mm Displacement| Parameter | Expected Impact ||-----------|-----------------|| **Hot spot location** | Shifted 8mm from planned || **Coverage of target** | May create underdose in specific region || **Dose gradient** | Steep gradient areas most affected || **Clinical significance** | Depends on target margin and bent...

**Scores:**
- Total: 0.65
- Keyword: 0.00
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1851](../screenshots/15_Q1851.png)

**Failure Analysis:**
- Root Cause: keyword_missing
- Description: No expected keywords found

---

### ❌ Q1852

**Input:** The medical physicist discovers that a brachytherapy source was not properly calibrated at the vendor before shipment. The source certificate shows air-kerma strength that does not match the expected decay calculation. The source has already been used for 5 patient treatments. What verification steps should be taken? Are the delivered doses accurate? What clinical actions are needed?...

**Response:**
> This is a serious quality assurance incident that requires immediate investigation and careful clinical assessment. Here's a comprehensive approach:## Immediate Verification Steps**1. Source Certificate Analysis**- Compare the certified air-kerma strength (AKS) against expected value based on:  - Source model and batch  - Reference date on certificate  - Decay calculation using the correct half-life (Ir-192: 73.83 days; Co-60: 1925.28 days)- Calculate the percentage deviation from expected**2. Independent Verification**- Measure the source with your well chamber (should have current calibration certificate)- Compare measured AKS against certificate value- Perform independent TG-43 calculation using measured AKS**3. Determine Magnitude of Error**- Document the actual AKS vs...

**Scores:**
- Total: 0.72
- Keyword: 0.20
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1852](../screenshots/15_Q1852.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ❌ Q1853

**Input:** A brachytherapy plan for prostate cancer was approved and delivered, but the physicist later realizes the prescription point was placed in the wrong location, resulting in the entire prostate receiving 20% less than intended. What is the clinical impact? Should a supplemental treatment be considered? How should this planning error be documented and reported?...

**Response:**
> This is a significant planning error requiring careful clinical assessment. Here's a comprehensive analysis:## Clinical Impact Assessment**Dose Relationship Context:**- Standard I-125 prescription: 145 Gy- 20% reduction → ~116 Gy delivered- For HDR boost (e.g., planned 9.5 Gy × 2): → ~7.6 Gy per fraction**Oncologic Risk:**The clinical significance depends on the treatment intent:| Scenario | Clinical Impact ||----------|-----------------|| **LDR monotherapy** | Moderate-high risk of reduced tumor...

**Scores:**
- Total: 0.72
- Keyword: 0.20
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1853](../screenshots/15_Q1853.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ❌ Q1854

**Input:** During HDR brachytherapy fraction 3 of 5, the medical physicist notices that the applicator position has shifted significantly compared to the planning CT from fraction 1. The tandem appears to have moved 15 mm superiorly. How should the treatment plan be adapted? Should the plan be recalculated? What imaging should be obtained to reassess?...

**Response:**
> A 15 mm tandem shift is clinically significant and requires action before proceeding with fraction 3.## Immediate Actions**1. Do NOT proceed with the current plan**- The shift alters source dwell positions relative to anatomy- OAR doses may be substantially different**2. Obtain verification imaging**- CBCT or repeat CT with applicator in place- Compare applicator position to planning CT- Assess tumor position relative to applicator## Options for Management| Option | When to Use | Action ||--------|-------------|--------|| **Replan** | Large shift with dosimetric impact | New CT → new plan for remaining fractions || **Shift-based adaptation** | Shift...

**Scores:**
- Total: 0.72
- Keyword: 0.20
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1854](../screenshots/15_Q1854.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ❌ Q1855

**Input:** A radioactive sealed source used for HDR brachytherapy is discovered to have a damaged capsule during a routine visual inspection. There is no visible leakage, but the capsule shows a small dent. What immediate actions should be taken? Should the source be replaced? What safety assessments are needed? How should this be reported to regulatory authorities?...

**Response:**
> ## Damaged HDR Source Capsule: Response Protocol### Immediate Actions1. **Remove source from service immediately**   - Place the source in the shielded container/afterloader safe   - Do not use the source for patient treatment   - Restrict access to the area2. **Radiation survey**   - Perform wipe tests for radioactive contamination   - Measure surface and ambient radiation levels   - Document all readings3. **Notify key personnel**   - Radiation Safety Officer (RSO)   - Chief Physicist   - Radiation Oncologist   - Department leadership### Safety Assessments Required| Assessment | Purpose ||------------|---------|| Visual inspection | Document extent of damage with photography || Leak test (wipe test) | Verify no radioactive material escaped || Exposure rate measurement | Quantify any increase in emissions...

**Scores:**
- Total: 0.72
- Keyword: 0.20
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1855](../screenshots/15_Q1855.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ❌ Q1856

**Input:** The treatment planning system generates a brachytherapy plan where the dwell times sum to an unusually long total treatment time (45 minutes for a single HDR fraction). The expected time should be approximately 15 minutes. Investigation reveals that one dwell position has an dwell time of 38 minutes due to an optimization error. What are the implications? How should this be caught during plan review?...

**Response:**
> ## Analysis of the 38-Minute Dwell Time Error### Implications**Dosimetric Impact:**- The single position would receive approximately 2.5x the intended dwell time- If prescription was 6 Gy to a point, this position would receive ~15 Gy instead of 6 Gy- This creates a severe hot spot (250% of prescription dose)- Local tissue overdose could cause necrosis, fistula, or other severe complications**Treatment Time Implications:**- Source decay during extended treatment: Ir-192 decays ~1.1% per hour, so a 45-minute treatment vs. 15-minute treatment results in ~0.3% additional decay- Patient discomfort and movement risk during extended treatment- Increased staff radiation exposure (longer room occupancy)**Clinical Consequences if Delivered:**-...

**Scores:**
- Total: 0.72
- Keyword: 0.20
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1856](../screenshots/15_Q1856.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ❌ Q1857

**Input:** After prostate LDR seed implantation, the patient develops acute urinary retention requiring catheterization within 6 hours of the procedure. The post-implant CT shows significant edema (prostate volume increased 45% from pre-implant). Is this expected? How should the acute urinary retention be managed? What modifications to the post-implant dosimetry should be made to account for edema?...

**Response:**
> ## Acute Urinary Retention After Prostate LDR Brachytherapy### Is 45% Edema Expected?**Yes, this is within expected range.** Post-implant prostate edema:- **Typical magnitude**: 20-50% volume increase- **Onset**: Peaks within 24-48 hours post-implant- **Resolution**: Typically resolves over 2-4 weeks- **Causes**: Needle trauma, edema from the procedure itself, inflammatory response45% increase is notable but not unusual, particularly with larger glands or more needles placed.### Acute Urinary Retention Management|...

**Scores:**
- Total: 0.72
- Keyword: 0.20
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1857](../screenshots/15_Q1857.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ❌ Q1858

**Input:** During brachytherapy for cervical cancer, the MRI performed at fraction 2 shows that the tumor has decreased by 40% compared to the MRI at fraction 1. How should the treatment plan be adapted? Should the dose prescription be modified? What are the implications for the cumulative dose to the HR-CTV and organs at risk?...

**Response:**
> ## Adaptive Brachytherapy for Cervical Cancer: Tumor Response Management### Clinical ScenarioTumor regression of 40% between fractions represents significant response and is exactly what adaptive brachytherapy (IGABT) is designed to address.### Treatment Plan Adaptation**Yes, the plan should be adapted.** This is the core principle of MRI-guided adaptive brachytherapy (IGABT).**Step-by-step approach:**1. **Image Acquisition**   - Obtain MRI at each brachytherapy fraction (or at minimum at fractions 1, 3, and 5)   - T2-weighted sagittal and axial sequences are standard   - Assess: tumor volume, applicator position, OAR position relative to applicator2. **Target Delineation on Repeat MRI**   - Re-contour HR-CTV based on residual tumor only   - IR-CTV may be reduced if parametric spread has improved   - Document the adapted...

**Scores:**
- Total: 0.72
- Keyword: 0.20
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1858](../screenshots/15_Q1858.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ❌ Q1859

**Input:** The physics team discovers that the CT-to-electron-density table used for brachytherapy planning has not been updated after the CT scanner software upgrade 2 months ago. All treatments during this period used the old table. What is the dosimetric impact? How many patients are affected? What clinical actions are needed?...

**Response:**
> # CT-ED Table Not Updated After Software Upgrade: Analysis and Actions## What is the CT-ED Table?The CT-to-electron-density (CT-ED) table converts Hounsfield Units (HU) to electron density (relative to water) for dose calculation. While brachytherapy is less sensitive to CT-ED calibration than external beam, discrepancies can still affect dose accuracy.## Potential Dosimetric Impact| Factor | Impact Assessment ||--------|-------------------|| **Magnitude** | Typically 1-5% dose error if table is significantly off || **Brachytherapy sensitivity** | **Lower** than EBRT — brachytherapy dose is calculated via TG-43 using source strength, not CT-based MC || **If using model-based dose calc (Monte Carlo)**: | Higher impact (5-15% possible) || **If using TG...

**Scores:**
- Total: 0.72
- Keyword: 0.20
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1859](../screenshots/15_Q1859.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ❌ Q1860

**Input:** During brachytherapy treatment, the radiation area monitor alarms indicate elevated radiation levels in the hallway outside the brachytherapy suite. Investigation reveals that the shielded door was not fully closed during treatment delivery. What is the radiation exposure to individuals in the hallway? What immediate actions should be taken? How should this be reported?...

**Response:**
> This is a significant radiation safety event that requires immediate response.## Immediate Actions1. **Evacuate the hallway area** - Post temporary barrier, prevent staff/public access2. **Terminate the treatment** - Abort the current fraction immediately3. **Confirm source retraction** - Verify source has returned to safe position4. **Account for all individuals** - Determine who was in the hallway during treatment and estimate their exposure time5. **Notify Radiation Safety Officer (RSO)** - Immediately## Radiation Exposure Assessment**Factors affecting exposure:**- HDR Ir-192 source activity (typically 10 Ci = 370 GBq)- Distance from source to hallway- Door shielding deficit (partial closure vs. gap)- Treatment duration that occurred with door open**Estimated exposure:**- At 1 meter from unshielded Ir-192 source: ~10 mSv/hr per cur...

**Scores:**
- Total: 0.72
- Keyword: 0.20
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1860](../screenshots/15_Q1860.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ❌ Q1861

**Input:** A brachytherapy plan for vaginal cancer was calculated using the wrong applicator model. The plan assumed a 2.5 cm vaginal cylinder but a 3.0 cm cylinder was actually used. The plan was delivered for 2 fractions before the error was discovered. What is the dosimetric impact? How should the remaining fractions be managed? What documentation is needed?...

**Response:**
> # Wrong Applicator Model in Vaginal Brachytherapy: Dosimetric Impact and Management## Dosimetric Impact Analysis**Key Finding: The patient received UNDERDOSE due to the wrong cylinder size.**| Parameter | Effect of Using 3.0 cm vs 2.5 cm Cylinder ||-----------|------------------------------------------|| **Source-to-wall distance** | Increased by 5 mm || **Dose at vaginal surface** | ~15-20% lower || **Dose at 5 mm depth** | ~10-15% lower || **Dose falloff pattern** | Shifted outward |**Specific Calculations:**- Using a 3.0 cm cylinder with the 2.5 cm prescription parameters means the actual dose delivered is approximately **70-85% of intended**- If prescription was 5 Gy to vaginal surface, actual delivered was ~3.5-4.25 Gy per fraction- Cumulative 2-fraction underdose: **...

**Scores:**
- Total: 0.72
- Keyword: 0.20
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1861](../screenshots/15_Q1861.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ✅ Q1862

**Input:** During LDR prostate seed implantation, the physicist realizes mid-procedure that 2 seeds from a different seed model (different activity and half-life) were accidentally loaded into the seed loader. Approximately 8 seeds of the wrong model have already been implanted. What are the implications? How should this be managed? Can the post-implant dosimetry account for the mixed seed models?...

**Response:**
> ## Management of Mixed Seed Model Error During LDR Prostate Implantation### Immediate Actions**Stop the procedure if possible:**- If more seeds remain to be implanted, halt until the situation is assessed- Verify which seeds are the correct model and which are the wrong model- Document the serial numbers of all implanted seeds**Don't remove implanted seeds:**- Removing seeds introduces additional trauma and risk- The implanted seeds will contribute to the final dose calculation### Implications of Mixed Seed Models**Different activity (air-kerma strength):**- If wrong seeds have higher activity: increased dose to surrounding tissue- If wrong seeds have lower activity: reduced tumor coverage in those regions- Typical I-125 models (e.g., Oncura OncoSeed vs. Best Medical) have similar but not identical TG-43 parameters**Different half-life:**- I-125:...

**Scores:**
- Total: 0.79
- Keyword: 0.40
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1862](../screenshots/15_Q1862.png)

---

### ❌ Q1863

**Input:** The quality assurance review reveals that a brachytherapy plan was delivered without the required independent dose verification check. The plan was approved and treated. What are the implications of this QA bypass? Should the delivered dose be verified retrospectively? What process changes are needed to prevent recurrence?...

**Response:**
> ## QA Bypass: Missing Independent Dose Verification### Implications of the QA Bypass**Immediate Risk Assessment:**- Cannot confirm dose accuracy without independent verification- Potential for calculation errors (TG-43 parameter entry, dwell time sum, applicator reconstruction)- Loss of quality assurance safeguard that typically catches 1-2% of plans with significant errors**Severity Classification:**- This is a **protocol deviation**, not necessarily a patient harm event- Depends on whether an actual dose error exists (unknown without retrospective analysis)---### Recommended...

**Scores:**
- Total: 0.72
- Keyword: 0.20
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1863](../screenshots/15_Q1863.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ❌ Q1864

**Input:** After HDR brachytherapy for endometrial cancer, the patient develops a pelvic abscess at the needle insertion sites 5 days post-procedure. The patient has fever and elevated WBC. How should the infection be managed? Does the infection affect the radiation treatment course? What antibiotics are recommended? Should the remaining fractions be delayed?...

**Response:**
> ## Pelvic Abscess Following Interstitial Brachytherapy for Endometrial Cancer### Immediate Management**Clinical Assessment:**- Blood cultures (aerobic and anaerobic)- CT-guided drainage if collection is >3-4 cm and accessible- Complete blood count, CRP, procalcitonin- Assess for sepsis (fever, tachycardia, hypotension)**Drainage:**- Image-guided percutaneous drainage is first-line for accessible collections- Surgical drainage if percutaneous approach fails or is not feasible- Send fluid for culture, Gram stain, and sensitivity### Antibiotic Recommendations**Empiric therapy** (pending cultures):- Broad-spectrum coverage: Piperacillin-tazobactam OR Meropenem- Add...

**Scores:**
- Total: 0.72
- Keyword: 0.20
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1864](../screenshots/15_Q1864.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ❌ Q1865

**Input:** A physicist discovers that the source dwell positions in the TPS were entered with a 2 mm systematic error in the superior-inferior direction for all 5 fractions of a cervical brachytherapy treatment. The patient has completed all fractions. What is the cumulative dosimetric impact? How should this systematic error be assessed? What clinical follow-up is needed?...

**Response:**
> This is a legitimate quality assurance scenario. Let me provide a comprehensive analysis.## Dosimetric Impact of 2mm Systematic Dwell Position Error### Magnitude of ErrorA 2mm systematic error in the superior-inferior direction affects all dwell positions uniformly. For cervical brachytherapy with tandem and ring/ovoid applicators:**Target Coverage Impact:**- HR-CTV may be underdosed by **5-15%** depending on tumor location relative to shifted dwell positions- The error shifts the entire dose distribution — structures at the superior/inferior margins receive shifted dose- For tumors positioned at the cervical os, a 2mm shift could move the prescription isodose away from the tumor centroid**OAR Impact:**- Bladder and rectum are position-sensitive — a 2mm shift could either increase or decrease dose depending on anatomical relationship...

**Scores:**
- Total: 0.72
- Keyword: 0.20
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1865](../screenshots/15_Q1865.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ❌ Q1866

**Input:** During prostate brachytherapy post-implant dosimetry, the physicist finds that the CT was acquired with the patient in a different position than the pre-plant ultrasound (supine vs. lithotomy). This has caused significant differences in seed positions relative to the prostate. How does this positioning difference affect dosimetry? Should the plan be recalculated? What quality assurance steps could have prevented this?...

**Response:**
> ## Impact of CT vs. TRUS Positioning on Prostate Brachytherapy Dosimetry### How Positioning Differences Affect Dosimetry**Geometric Changes:**- Lithotomy position elongates the pelvis and can displace the prostate anteriorly relative to the pelvic bones- Prostate orientation changes (increased rotation)- Bladder filling differences alter anterior-posterior relationships- Rectum position varies with patient positioning**Dosimetric Consequences:**| Effect | Typical Magnitude ||--------|------------------|| Prostate apex shift | 3-8 mm AP || Base displacement | 5-12 mm || Seed-prostate spatial mismatch | 2-5 mm systematic || D90 variation | ±10-15% || V100 variation | ±5-10% |**Specific Issues:**1. **...

**Scores:**
- Total: 0.65
- Keyword: 0.00
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1866](../screenshots/15_Q1866.png)

**Failure Analysis:**
- Root Cause: keyword_missing
- Description: No expected keywords found

---

### ❌ Q1867

**Input:** The radiation safety officer discovers that a brachytherapy patient left the hospital without completing the required radiation safety precautions discussion after LDR seed implant. The patient has seeds with activity of 0.4 mCi each. What radiation safety risks exist? How should the patient be contacted? What are the regulatory reporting requirements?...

**Response:**
> This is a legitimate radiation safety question. Let me provide a comprehensive response.## Radiation Safety Risks Assessment**Activity Level Analysis:**- 0.4 mCi per seed is typical for I-125 seeds (common activity range: 0.3-0.5 mCi)- For context: I-125 seeds typically contain 0.5-1.0 mCi activity at implantation- Total activity depends on number of seeds implanted (typically 60-100 seeds for prostate)**Patient Exposure Risk:**- External exposure from seeds in the body is minimal (low-energy photons)- Close contact exposure: At 1 meter, dose rate is typically <0.1 mSv/hour- No significant exposure risk to family members or the public at normal distances- Seeds in bladder may pass and could potentially...

**Scores:**
- Total: 0.72
- Keyword: 0.20
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1867](../screenshots/15_Q1867.png)

**Failure Analysis:**
- Root Cause: wrong_answer
- Description: Response does not meet expectations

---

### ✅ Q1868

**Input:** A brachytherapy treatment plan shows excellent dosimetric parameters, but the treating physician notices on the day of treatment that the applicator on the planning CT does not match the actual applicator inserted. The actual applicator has a longer tandem (7 cm vs 6 cm on plan). How should this be managed? Should the plan be recalculated? Can the plan be adapted intraoperatively?...

**Response:**
> This is a genuine safety scenario that requires immediate clinical management. Here's a comprehensive response:## Immediate Actions**Do NOT proceed with treatment using the incorrect plan.**1. **Stop the treatment** - The planned dwell positions are based on a 6 cm tandem; the actual 7 cm tandem will have different source positions relative to anatomy2. **Verify the discrepancy** - Confirm the actual tandem length with physical measurement or comparison to imaging3. **Assess the difference** - The 1 cm discrepancy affects:   - Dwell positions in the additional 1 cm of tandem   - Position of the ring/colpostats relative to the tandem tip   - Overall applicator geometry and angles##...

**Scores:**
- Total: 0.79
- Keyword: 0.40
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1868](../screenshots/15_Q1868.png)

---

### ❌ Q1869

**Input:** During quality assurance, the physicist discovers that the HDR afterloader's source transit time has increased by 30% compared to baseline measurements. The transit time has been gradually increasing over the past 3 months. What does this trend indicate? What maintenance is needed? Are treatments delivered during this period affected? What is the tolerance for transit time?...

**Response:**
> This represents a **potential equipment malfunction** requiring investigation before proceeding with treatments.## Transit Time Increase - Analysis**What the 30% increase indicates:**- **Cable wear/degradation**: The source driving cable may be stretching, fraying, or developing resistance- **Mechanical friction**: Bearings or pulleys in the afterloader mechanism may be wearing- **Motor degradation**: The source drive motor may be losing torque- **Environmental factors**: Temperature changes affecting cable properties**Tolerance for transit time:**Per AAPM TG-56 and manufacturer specifications, typical tolerances are:- **Dwell position accuracy**: ±1 mm (some manufacturers allow 2-3 mm)- **Transit time tolerance**: Generally ±10% of nominal value- **30% increase exceeds acceptable limits**## Clinical Impact on...

**Scores:**
- Total: 0.65
- Keyword: 0.00
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1869](../screenshots/15_Q1869.png)

**Failure Analysis:**
- Root Cause: keyword_missing
- Description: No expected keywords found

---

### ❌ Q1870

**Input:** A brachytherapy plan was created and approved on a Wednesday. The patient was scheduled for treatment on Thursday but the source was exchanged on Friday. The new source has different activity due to decay. How should the plan be adapted for the new source? What recalculations are needed? Can the same dwell times be used with the new source?...

**Response:**
> ## Source Exchange Impact on Brachytherapy Plan**Key Principle:** The same dwell times CANNOT be used with a new source. The plan must be recalculated.### Why Dwell Times ChangeHDR brachytherapy dose is proportional to:- Source activity (air-kerma strength)- Dwell time- Distance from sourceIf source activity changes due to decay or exchange, dwell times must be proportionally adjusted to deliver the prescribed dose.### Required Actions| Step | Action ||------|--------|| **1. Verify new source strength** | Obtain certificate for new source; enter air-kerma rate into TPS || **2. Calculate decay factor** | (New activity / Old activity) or account for time elapsed || **3. Recalculate dwell times** | Multiply original dwell times by: (Old air-kerma / New air...

**Scores:**
- Total: 0.65
- Keyword: 0.00
- Completeness: 1.00
- Safety: 1.00
- Accuracy: 1.00
- Ux: 1.00
- Language: 1.00

**Screenshot:**
![Q1870](../screenshots/15_Q1870.png)

**Failure Analysis:**
- Root Cause: keyword_missing
- Description: No expected keywords found

---

